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subpopulation, 140 patients received tigecycline mono-
therapy, 75 were treated with combination regimens. High 
overall clinical success rates were recorded for MRB infec-
tions treated with tigecycline alone (94 %) or in combina-
tions (88 %); in detail intraabdominal infections (mono-
therapy: 90 %; combinations: 93 %), skin/soft tissue 
infections (93; 100 %), community-acquired pneumonia 
(100; 100 %), hospital-acquired pneumonia (94,7; 72,7 %), 
diabetic foot infections (89; 33 %), blood stream infections 
(100; 100 %) and multiple-site infections (92; 71 %).
Conclusions Tigecycline achieved high clinical success 
rates in patients with documented infections involving 
MRB strains despite high disease severity. These results 
add to the evidence indicating that tigecycline is a valuable 
therapeutic option for complicated infections in severely ill 
patients with a high likelihood of multidrug-resistant path-
ogen involvement.
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Purpose
Tigecycline is a glycylcycline antibiotic with a broad 
spectrum of antimicrobial activity covering bacteria with 
resistance against multiple antibiotics (MRB) such as van-
comycin-resistant enterococci (VRE), methicillin-resist-
ant Staphylococcus aureus (MRSA), extended-spectrum 
beta-lactamase producing Enterobacteriaceae (ESBL) and 
strains of the Acinetobacter baumannii group [1–4].
In the US [5] and Europe [6], tigecycline is approved 
for the treatment of complicated intraabdominal infections 
Abstract 
Introduction Tigecycline is an established treatment option 
for infections with multiresistant bacteria (MRB). It retains 
activity against many strains with limited susceptibility to 
other antibiotics. Efficacy and safety of tigecycline as mono-
therapy or in combination regimens were investigated in a 
prospective noninterventional study involving 1,025 severely 
ill patients in clinical routine at 137 German hospitals.
Materials and methods Data on the full population have 
been published; our present analysis focuses on infec-
tions caused by MRB. The study population included 
patients with complicated infections, high disease sever-
ity (APACHE II > 15: 65 %) and high MRB prevalence. 
Most patients had comorbidities, including cardiovascular 
disease, renal insufficiency, and/or diabetes mellitus. Treat-
ment success was defined as cure/improvement without 
requirement of further antibiotic therapy.
Results Pathogens isolated from 215 evaluable patients 
with documented MRB infections included 132 methicil-
lin-resistant Staphylococcus aureus (MRSA), 42 vanco-
mycin-resistant Enterococci (VRE) and 67 Gram-negative 
extended beta-lactamase (ESBL) producers. Of the MRB 
W. R. Heizmann (*) 
Orgamed Laborsysteme GmbH, Maria-Schmid-Str. 14b, 
94086 Bad Griesbach, Germany
e-mail: wrheizmann@aol.com; orgamed.consulting@aol.com
P.-A. Löschmann · C. von Eiff · C. Petrik 
Pfizer Pharma GmbH, Linkstraße 10, 10785 Berlin, Germany
C. Eckmann 
Klinikum Peine, Virchowstraße 8 h, 31221 Peine, Germany
K.-F. Bodmann 
Klinikum Barnim GmbH, Rudolf-Breitscheid-Straße 36, 
16225 Eberswalde, Germany
38 W. R. Heizmann et al.
1 3
(cIAI) and complicated skin and skin tissue infections 
(cSSTI). In the US, tigecycline is also indicated for com-
munity-acquired bacterial pneumonia.
The patient population in the two pivotal phase III stud-
ies on tigecycline in cIAI had a relatively low mean ini-
tial APACHE II score of 6.3, as patients with APACHE II 
scores >30 were excluded [7]. The number of severely ill 
patients was limited in both phase III cSSTI trials as well 
[8]. Thus, published data from prospective (comparative) 
trials on tigecycline used in higher risk patients with com-
plicated, pre-treated infections and high risk of drug-resist-
ant pathogens are limited.
Most data on tigecycline in severely ill patients are 
derived from retrospective analyses or studies focused 
on identified pathogens rather than clinical syndromes. 
Bassetti et al. [9] reported on a single-center prospec-
tive observational study of tigecycline in severely ill 
patients with various complicated infections. The authors 
found high response rates for peritonitis, cSSTI and blood 
stream infections despite unfavorable patient risk profiles 
(mean APACHE II score 21; high prevalence of severe 
comorbidities).
In recent years, Enterobacteriaceae developed a range 
of antimicrobial resistances that reduce therapeutic choices 
to a very limited set of active antibiotics. The spread of 
ESBL-producers and bacterial strains expressing carbap-
enemases is causing much concern on the future options 
of effective antibacterial therapy in hospitals [10]. In addi-
tion, in the Gram-positive spectrum of pathogens, MRSA 
remains a threat in cSSTI [11], DFI [12], and hospital-
acquired pneumonia (HAP) [13], while VRE are commonly 
implicated in severe cIAI and blood stream infections (BSI) 
[14]. Because these pathogens are commonly found in 
infections taking a severe course, tigecycline becomes an 
increasingly important treatment option for a broad range 
of severe infections, particularly as empirical therapy in 
patients at risk for MRB.
Consequently, there is a need for additional clinical data 
to evaluate the usefulness of tigecycline, thereby provid-
ing additional evidence for the rational and safe use of this 
antibiotic.
This sub-analysis of a prospective, non-interventional 
study investigated the efficacy and safety of tigecycline 
used alone or in combination in the real-life hospital set-
ting in Germany. Results obtained in the total patient 
population have been published before [15]. Here, we 
present data on patients suffering from infections with 
documented involvement of bacteria exhibiting multidrug-
resistant phenotypes. We characterized the subpopulation 
treated with tigecycline for these infections in various 
indications and determined treatment outcomes associated 
with tigecycline used alone or in combination with other 
antimicrobials.
Methods
Details on the methodology of the non-interventional par-
ent study have been published before [15]. Briefly, hospi-
tal-based physicians prospectively documented data on 
patients treated with tigecycline for cIAI, cSSTI or other 
severe infections according to local routine practice. The 
population observed in this study included severely ill 
patients with previous/failed antimicrobial treatment and/
or involvement of drug-resistant pathogens. Infections were 
classified as hospital vs. community acquired depending on 
the first manifestation of the infection after or before 48 h 
of hospitalization. The study protocol involved an initial 
intravenous dose of 100 mg of tigecycline (Tygacil®; Pfizer 
Pharma GmbH, Berlin, Germany), followed by 50 mg tige-
cycline every 12 h, as recommended in the product label.
The present analyses include only those patients who 
had infections with documented involvement of multire-
sistant bacteria (VRE, MRSA, ESBL-producers) and evalu-
able treatment outcomes. ESBL-production was detected 
by combination disk testing with clavulanic acid or VITEK 
II, methicillin resistance by testing cefoxitin and VRE by 
E-test, breakpoint agars, or VITEK II according to the pro-
tocol of the local microbiology laboratory.
Table 1  Patient demographics, comorbidities and severity scores at 
baseline
Patient demographics Total population Patients with MRB
Number of patients, n 1,025 256
Demographic characteristics
 Male,  % (n) 62.8 % (642) 64.8 % (166)
 Age, mean 
years ± SD  
(range)
64.4 ± 13.7 (18–94) 66.5 ± 12.0 (19–88)
Clinical characteristics
 BMI, mean,  
kg/m2 ± SD  
(range)
27.7 ± 6.5 (14–90) 28.4 ± 7.0 (14.6–58.8)
 Treatment on  
ICU,  % (n)
53.2 % (545) 41.8 % (107)
 History of prior  
antibiotics,  % (n)
84.5 % (864) 83.2 % (213)
 Comorbidity,  % (n) 96.5 % (989) 96.1 % (246)
 APACHE II score 
>15,  % (n)
64.9 % (607) 68.4 % (162)
 APACHE II score, 
mean (median)
18.8 (18.0) 19.4 (19.0)
Patients with  
treatment on  
ICU
20.0 (20.0) 21.4 (21.0)
Patients with  
treatment  
outside ICU
17.3 (17.0) 17.9 (18.0)
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The investigators rated the therapeutic outcome as cure, 
improvement with no further need for antibiotic treatment, 
failure to respond or not evaluable. Rating the outcome 
as cure required full resolution of symptoms of infection, 
whereas improvement was defined as significant improve-
ment of symptoms but without complete resolution of 
infection. Outcome was rated 1–3 days after the end of 
tigecycline therapy or at hospital discharge. Treatment suc-
cess was defined as cure or improvement with no further 
need for antibiotic treatment.
Results
Patient demographic and clinical characteristics
1025 patients were treated with tigecycline in 137 German 
hospitals. Of these patients, 256 had infections due to mul-
tiresistant bacteria. Demographic and clinical characteris-
tics of evaluable patients are presented in Table 1.
A large proportion of this predominantly elderly MRB 
subpopulation (mean age: 66.5 years) was treated on inten-
sive care units (41.8 %). The median APACHE II score 
was 21.5. Virtually all patients had at least one comorbid-
ity. Most patients (83.2 %) had received prior therapy with 
other antibiotics.
Pathogens and sites of infection
MRSA was the most commonly isolated multiresistant 
pathogen (61.4 % of the patients), followed by ESBL-pro-
ducers (31.2 %) and VRE (19.5 %) (Table 2). Most patients 
with MRB had cIAI (32.6 %) or cSSTI (25.6 %), followed 
by other severe infections, such as hospital- or community-
acquired pneumonia (20.0 %), diabetic foot infections 
(DFI; 14.0 %), blood stream infections BSI (10.2 %) or 
multiple-site infections (MSI; 12.6 %). MRSA was the pre-
dominant pathogen in patients with cSSTI (90.9 %), CAP 
(84.6 %), HAP (70.0 %), DFI (100 %) and BSI (68.2 %). 
ESBL-producers were the most common MRB in patients 
with cIAI (50.0 %) and VRE were the second most patho-
gens isolated in patients with cIAI (38.6 %).
Mode and duration of therapy
The great majority of patients (initial dose ≥95.7 %; main-
tenance doses ≥91.9 %) received tigecycline at the recom-
mended dosage1 as monotherapy (65.1 %) or in combina-
tion regimens (34.9 %) (Table 3). Combination therapy was 
most common in cIAI (40.0 %). Most patients treated with 
combination regimens received ceftazidime, a carbapenem, 
a fluoroquinolone or metronidazole in addition to tigecy-
cline (Table 4).
Median treatment duration was 8 days for BSI (range 
4–17), 9 days for HAP (5–17), 10 days for IAI (2–40) and 
CAP (7–15), 11 days for SSTI (4–33) and DFI (4–42), and 
12 days for MSI (5–42).
Clinical outcome
The clinical outcome of tigecycline treatment per patient 
subgroup is shown in Tables 5 and 6. Treatment success 
rates were generally in the range of 80–100 % regardless of 
the type of involved MRB.
Complicated IAI were successfully treated in 91.4–
96.3 %. HAP success rates were somewhat higher with 
MRSA (94.7 %) than with ESBL-producers (88.8 %), but 
the patient number was low in the latter subgroup. Tige-
cycline was effective in most DFI (83.3 %) which were 
almost exclusively caused by MRSA. In cSSTI, again dom-
inated by MRSA, an overall success rate of 94.5 % was 
observed. The treatment success rate was 100 % for BSI 
and CAP in all MRB subgroups. Patients with multiple-site 
MRB infections had a success rate of 81.5 %.
1
 Initial dose was not reported in 1 patient; maintenance dose was 
not reported in 10 patients. The following divergent dosage regi-
mens were reported: initial dose: 50 mg (7 patients), 70 mg (1), 2 x 
100 mg (1), not specified (1); maintenance doses: 25 mg twice daily 
(1); 25 mg twice weekly (1); 50 mg once daily (5); 100 mg once daily 
(1) 100 mg twice daily (1), 150 mg twice daily (1); not specified (1).
Table 2  Distribution of 
multiresistant bacteria by site 
of infection (patients with 
evaluable treatment outcome; 
n = 215)
Patients could have more than 
one MRB
Drug-resistance phenotype,  % (n) Patients with documented MRB infection
Any MRB VRE MRSA ESBL
Total MRB population 100 % (215) 19.5 % (42) 61.4 % (132) 31.2 % (67)
Intraabdominal infection (cIAI) 32.6 % (70) 38.6 % (27) 27.1 % (19) 50.0 % (35)
Skin and soft tissue infection (cSSTI) 25.6 % (55) 5.5 % (3) 90.9 % (50) 7.3 % (4)
Diabetic foot infection (DFI) 14.0 % (30) −(0) 100.0 % (30) 10.0 % (3)
Community-acquired pneumonia (CAP) 6.0 % (13) 7.7 % (1) 84.6 % (11) 38.5 % (5)
Hospital-acquired pneumonia (HAP) 14.0 % (30) −(0) 70.0 % (21) 30.0 % (9)
Blood stream infection (BSI) 10.2 % (22) 18.2 % (4) 68.2 % (15) 36.4 % (8)
Multiple-site infection (MSI) 12.6 % (27) 14.8 % (4) 63.0 % (17) 44.4 % (12)
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Regarding treatment modality, the success rate was 
93.6 % for monotherapy, with rates ranging from 89.9 to 
100 % for the different types of infection and drug-resistant 
bacteria (Fig. 1a; Table 6).
Using combination therapies, 88.0 % of the patients 
were successfully treated, with rates ranging from 71.4 % 
to 100 % for all types of infections. The rate was lower in 
DFI (33.3 %), albeit based on only 3 patients in this sub-
group (Fig. 1b; Table 6).
Discussion
The patients analyzed in this subpopulation with MRB 
infections were treated with tigecycline in routine settings 
in German hospitals. They suffered from complicated IAI, 
Table 3  Mode of therapy in patients with multiresistant pathogens 
by site of infection (patients with evaluable treatment outcome; 
n = 215)
Patients could have more than one MRB; 2 patients with HAP were 
diagnosed with BSI as well, these were not categorized as MSI 
because the lung infection was regarded as the focus of BSI
Proportion of patients,  % (n) Monotherapy Combination therapy
Total MRB population 65.1 % (140) 34.9 % (75)
Intraabdominal infection (cIAI) 28.6 % (40) 40.0 % (30)
Skin and soft tissue infection 
(cSSTI)
31.4 % (44) 14.7 % (11)
Diabetic foot infection (DFI) 19.3 % (27) 4.0 % (3)
Community-acquired  
pneumonia (CAP)
8.6 % (12) 1.3 % (1)
Hospital-acquired pneumonia 
(HAP)
13.6 % (19) 14.7 % (11)
Blood stream infection (BSI) 12.9 % (18) 5.3 % (4)
Multiple-site infection (MSI) 9.3 % (13) 18.7 % (14)
Table 4  Antibiotics most commonly administered in combination 
with tigecycline (patients with evaluable treatment outcome; n = 215)
Antibiotic agent Patients,  % (n)
All agents 34.9 %(75)
Ceftazidime 11.2 %(24)
Carbapenem (meropenem, imipenem) 5.6 %(12)
Fluoroquinolone (ciprofloxacin, levofloxacin) 4.7 %(10)
Metronidazole 3.7 % (8)
Piperacillin (±tazobactam) 1.9 % (4)
Vancomycin 1.4 % (3)
Cefepime 1.4 % (3)
Sulbactam 0.9 % (2)
Clindamycin 0.9 % (2)
Gentamicin 0.9 % (2)
Others 2.3 % (5)
Table 5  Treatment success rates (cure + improvement) in patients with multiresistant pathogens by drug-resistance phenotype (patients with 
evaluable treatment outcome; n = 215)
Patients could have more than one MRB
Treatment success  % (n/N) Patients with documented MRB infection
Any MRB VRE MRSA ESBL
Total MRB population 91.6 % (197/215) 97.6 % (41/42) 90.2 % (120/132) 91.0 % (61/67)
Intraabdominal infection (cIAI) 91.4 % (64/70) 96.3 % (26/27) 89.5 % (17/19) 91.4 % (32/35)
Skin and soft tissue infection (cSSTI) 94.5 % (52/55) 100 % (3/3) 94.0 % (47/50) 100 % (4/4)
Diabetic foot infection (DFI) 83.3 % (25/30) −(0/0) 83.3 % (25/30) 66.6 % (2/3)
Community-acquired pneumonia (CAP) 100 % (13/13) 100 % (1/1) 100 % (11/11) 100 % (5/5)
Hospital-acquired pneumonia (HAP) 86.7 % (26/30) −(0/0) 85.7 % (18/21) 88.8 % (8/9)
Blood stream infection (BSI) 100 % (22/22) 100 % (4/4) 100 % (15/15) 100 % (8/8)
Multiple-site infection (MSI) 81.5 % (22/27) 100 % (4/4) 76.5 % (13/17) 83.3 % (10/12)
Table 6  Treatment success rates (cure + improvement) in patients 
with multiresistant pathogens by mode of therapy (patients with eval-
uable outcome; n = 215)
Treatment success  % (n/N) Monotherapy Combination therapy
Total MRB population 93.6 % (131/140) 88.0 % (66/75)
Intraabdominal infection 
(sIAI)
90.0 % (36/40) 93.3 % (28/30)
Skin and soft tissue  
infection (cSSTI)
93.2 % (41/44) 100 % (11/11)
Diabetic foot infection  
(DFI)
88.9 % (24/27) 33.3 % (1/3)
Community-acquired  
pneumonia (CAP)
100 % (12/12) 100 % (1/1)
Hospital-acquired  
pneumonia (HAP)
94.7 % (18/19) 72.7 % (8/11)
Blood stream infection  
(BSI)
100 % (18/18) 100 % (4/4)
Multiple-site infection  
(MSI)
92.3 % (12/13) 71.4 % (10/14)
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SSTI, and/or other severe infections involving multire-
sistant bacteria.
Rates of clinical cure or improvement were high in this 
subpopulation. A total of 91.6 % of patients with MRB 
infections were successfully treated, 93.6 % with mono-
therapy and 88.0 % with tigecycline combinations.
Success rates for monotherapy were consistently higher 
than 90 % for all multiresistant pathogens and higher than 
80 % for all disease types; rates were particularly high in 
BSI (100 %), CAP (100 %) and cSSTI (95 %).
The success rates tended to be somewhat lower in com-
bination therapies (88.0 vs. 93.6 % with monotherapy), 
mostly due to the response rates in patients with MSI 
(71.4 %), or HAP (72.3 %). This divergence may have been 
caused (1) by a higher likelihood of combination therapies 
being used in patients with higher disease severity, (2) the 
choice of the combination drug, (3) random effects due 
to small patient numbers, and (4) the likelihood of higher 
morbidity in patients with infection at multiple sites of 
infection.
Conversely, the treatment success rate of MRB nosoco-
mial pneumonia was 94.7 % in patients receiving tigecy-
cline monotherapy at standard dosage. This is a reassur-
ingly high rate in the light of data obtained in the phase III 
HAP study of tigecycline versus imipenem that failed to 
confirm the non-inferiority of tigecycline in the clinically 
evaluable patient subset. A subsequent phase II study with 
tigecycline used at higher dosages indicated increased effi-
cacy with a clinical cure rate of 85 % [16]. There are sev-
eral, at least, theoretical reasons why non-bactericidal anti-
microbial agents such as tigecycline are effective in severe 
infections [17].
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Fig. 1  Treatment success rates (cure + improvement) in patients 
with multiresistant pathogens a Monotherapy, b combination ther-
apy. IAI intraabdominal infection, BSI blood stream infection, CAP 
community-acquired pneumonia, DFI diabetic foot infection, HAP 
hospital-acquired pneumonia, MSI multiple-site infection, SSTI skin 
and soft tissue infection
42 W. R. Heizmann et al.
1 3
The limitations of this study include its non-controlled 
observational design that may be associated with several 
biases and uncertainties, and the lack of rigorous criteria 
of diagnosis and assessment of response. Despite these 
shortcomings, this analysis of a sizeable sample of patients 
with severe MRB infections provides evidence of the use-
fulness of tigecycline in this diverse and difficult-to-treat 
population.
Non-interventional studies provide insights into the real-
life utility of antibiotics beyond the preselected cohorts 
treated in randomized trials. Despite that patients infected 
with multiresistant bacteria are not excluded from pivotal 
trials, they usually do not represent a large proportion of 
the whole patient population. Observational studies are 
particularly useful for the evaluation of substances that are 
used in indications and situations outside the scope covered 
by pivotal trials, e.g., in patients with high-risk profiles, 
multiple comorbidities, highly resistant pathogens, exten-
sively pre-treated infections [18].
Conclusions
Our subpopulation analysis of the prospective tigecycline 
non-interventional study conducted in routine settings 
confirmed the efficacy of tigecycline in the treatment of 
severely ill patients with complicated, mostly pre-treated 
infections involving multidrug-resistant pathogens. Tigecy-
cline was administered at the recommended dose with few 
exceptions.
Tigecycline used alone or in combination was highly 
effective against infections caused by multidrug-resistant 
Gram-positive and Gram-negative pathogens in patients 
even with high disease severity.
These results add to the accumulating evidence indi-
cating that tigecycline is a valuable therapeutic option for 
complicated infections in severely ill patients at high risk 
of the involvement of multidrug-resistant pathogens.
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